S&P Futures
4,354.25 +16.75 (+0.39%) Dow Futures
34,022.00 +130.00 (+0.38%) Nasdaq Futures
14,943.50 +83.75 (+0.56%) Russell 2000 Futures
1,817.00 +7.90 (+0.44%) Crude Oil
91.80 +0.09 (+0.10%) Gold
1,889.70 +11.10 (+0.59%)
Aquestive Therapeutics, Inc. (AQST)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.5200 |
| Open | 1.5200 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 1000 |
| Day's Range | 1.4801 - 1.5200 |
| 52 Week Range | 0.7200 - 2.6900 |
| Volume | |
| Avg. Volume | 326,924 |
| Market Cap | 100.091M |
| Beta (5Y Monthly) | 2.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4000 |
| Earnings Date | Oct 30, 2023 - Nov 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.17 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AQST
Related Research
- Aquestive Therapeutics, Inc.Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.RatingFair ValueEconomic Moat2 days agoMorningstar
ZacksAquestive Therapeutics (AQST) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Aquestive Therapeutics (AQST) closed at $1.52, marking a -0.65% move from the previous day.
ZacksAquestive (AQST) Up on Reaffirming Anaphylm Development Pathway
Aquestive (AQST) stock rises 11.8% as the company intends to begin a pivotal pharmacokinetic study of Anaphylm as an oral epinephrine product candidate in the fourth quarter of 2023.
GlobeNewswireAquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film
WARREN, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided an update on the development timeline and pathway for its oral epinephrine product candidate, Anaphylm™. As previously disclosed, Aquestive submitted its revised protocol for the proposed pivotal PK clinical trial to the Food an
